Anti-LRFN2 Antibody

Product Name

Anti-LRFN2 Antibody

View all LRFN2 Antibodies

SKU/Catalog Number

A11623-1

Size

100 μl/vial

Form

Liquid

Description

Boster Bio Anti-LRFN2 Antibody catalog # A11623-1. Tested in WB, ELISA applications. This antibody reacts with Human, Mouse, Rat.

Storage & Handling

12 months from date of receipt，-20℃ as supplied. 6 months 2 to 8℃ after reconstitution. Avoid repeated freezing and thawing.

Cite This Product

Anti-LRFN2 Antibody (Boster Biological Technology, Pleasanton CA, USA, Catalog # A11623-1)

Host

Rabbit

Contents

500 μg/ml antibody with PBS, 0.02% NaN3, 1 mg stabilizing protein and 50% glycerol
This antibody is supplied in a stabilized formulation.
Compatibility with conjugation reactions depends on the chemistry of the conjugation method used.
For conjugation methods that are not compatible with the stabilizing components present in this formulation, a carrier-free antibody format is required.

Clonality

Polyclonal

Immunogen

E.coli-derived human LRFN2 recombinant protein (Position: E373-S483).

Reactive Species

A11623-1 is reactive to LRFN2 in Human, Mouse, Rat

Calculated molecular weight

84.7 kDa

Background of LRFN2

LRFN2, also known as SALM1. It is mainly located in cell membrane and cytoplasm, and it is expressed at the synaptic contact at the base of cone cells, especially at the base of presynaptic endings, which is closely related to the dendrites of OFF bipolar cells (PMID: 40251167). In mammals, LRFN2 is mainly expressed in cone cells, but not in rod cells, and its expression in other retinal neurons is limited. In addition, the expression level in embryonic nerve cells is relatively low, mainly in more mature cells. LRFN2 plays a key role in synaptic transmission between cone cells and OFF bipolar cells. It can maintain the physical connection between cone cells and OFF bipolar cells, and gather glutamate receptors at the postsynaptic membrane to ensure strong dendritic transmission in OFF pathway, thus participating in the transmission of visual signals, which is very important for the coding of visual contrast and the defense behavior driven by looming. In bladder cancer, the increased expression of LRFN2 will inhibit the infiltration and functional transformation of CD8+ T cells, thus weakening the anti-tumor immune response, leading to bladder cancer resistance to immune checkpoint inhibitors, and its high expression is related to the poor prognosis of bladder cancer patients (PMID:37802603).

Antibody Validation

Boster validates all antibodies on WB, IHC, ICC, Immunofluorescence, and ELISA with known positive control and negative samples to ensure specificity and high affinity, including thorough antibody incubations.

View more details

Applications

A11623-1 is guaranteed for ELISA, WB Boster Guarantee

Assay Dilutions Recommendation

The recommendations below provide a starting point for assay optimization. The actual working concentration varies and should be decided by the user.

Western blot, 1:500-2000
ELISA, 1:100-1000

Validation Images & Assay Conditions

There are currently no images for this product. We are working on uploading them please check back shortly or contact us to expedite our upload process for this antibody.

See full target information LRFN2

Here are featured tools and databases that you might find useful.

• Boster's Pathways Library
• Protein Databases
• Bioscience Research Protocol Resources
• Data Processing & Analysis Software
• Photo Editing Software
• Scientific Literature Resources
• Research Paper Management Tools
• Molecular Biology Software
• Primer Design Tools
• Bioinformatics Tools
• Phylogenetic Tree Analysis